-
2 weeks ago | 
clinicaltrialsarena.com | Frankie Fattorini
AI is said to be exponentially faster and effective at writing lengthy and complex clinical trial documents, but those using the technology see some limitations, which could mean a role for human medical writers endures. Large language models (LLMs) can draft clinical documents in a fraction of the time their human counterparts need. Growing interest from the pharmaceutical industry to harness this technology has therefore made specialised writers worry their livelihood is under threat.
-
2 weeks ago | 
pharmaceutical-technology.com | Frankie Fattorini
Skip to site menuSkip to page content AI is said to be exponentially faster and effective at writing lengthy and complex clinical trial documents, but those using the technology see some limitations, which could mean a role for human medical writers endures. Large language models (LLMs) can draft clinical documents in a fraction of the time their human counterparts need.
-
3 weeks ago | 
pharmaceutical-technology.com | Frankie Fattorini
Streeting said his ten-year plan will address drug sale clawbacks, NICE regulation, and the abolition of NHS England. Wes Streeting addressed the concerns of gathered UK pharma representatives at the 2025 ABPI conference in London. Credit: Frankie Fattorini / GlobalData.
-
3 weeks ago | 
medicaldevice-network.com | Frankie Fattorini
Under the mounting strain of an aging population, the UK could look to South Korean medtech innovation to ease the pressures of dementia care on the NHS. On April 2, medtech startups from South Korea showcased their technologies for dementia detection and care in London.
-
3 weeks ago | 
pharmaceutical-technology.com | Frankie Fattorini
Government drug sale clawbacks must be eased for pharma innovation to meet its 10-year plan, say industry representatives. ABPI chief executive Richard Torbett called for UK Government action on amending drug sale clawbacks under the VPAG scheme. Credit: Frankie Fattorini / GlobalData.
-
3 weeks ago | 
pharmaceutical-technology.com | Frankie Fattorini
Non-profit organisations provide an alternative to rescue stalled orphan drugs for biotechs struggling against a lethargic investment climate. With private and government funding falling short, developers may seek innovative strategies to push rare disease drugs through to clinical trials. Credit: wacomka / Getty Images.
-
1 month ago | 
businessandamerica.com | Frankie Fattorini
As cell and gene therapy developers struggle against an investment slump and competition from established autologous treatments, allogeneic cell therapies may still find a niche. Though still nascent, allogeneic options are “poised for prime time,” said Stefanos Theoharis, CEO of the Barcelona, Spain-based Onechain Immunotherapeutics, at the Advanced Therapies conference, in London on 18 March.
-
1 month ago | 
pharmaceutical-technology.com | Frankie Fattorini
As cell and gene therapy developers struggle against an investment slump and competition from established autologous treatments, allogeneic cell therapies may still find a niche. Though still nascent, allogeneic options are “poised for prime time,” said Stefanos Theoharis, CEO of the Barcelona, Spain-based Onechain Immunotherapeutics, at the Advanced Therapies conference, in London on 18 March.
-
1 month ago | 
pharmaceutical-technology.com | Frankie Fattorini
Innovation, collaboration, and regulatory reform were on the agenda at the 2025 Clinical Trial Supply Europe conference. Biopharma leaders met in Spain to discuss the ways how AI-optimised supply chains can safeguard clinical trials against global trade instability. Credit: gorodenkoff / Getty Images.
-
1 month ago | 
businessandamerica.com | Frankie Fattorini
In step with international news in recent times, European pharma and biotech are leaning towards ‘nearshoring’, preferring domestic operations to outsourcing abroad, experts say. But regionally focussed sentiment is to be limited and short-lived, they state, faced with globally cooperative markets and supply chains. “Firms are moving towards nearshoring,” says Dr. Pooja Thakur-Wernz, assistant professor of business administration at Washington and Lee University in Lexington, Virginia.
